Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a
syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the
most effective treatment remains unknown. This study is trying to evaluate the efficacy and
safety of PD-1 monoclonal antibody as a first-line therapy for EBV-HLH and CAEBV.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University